Thus, over-expression of estrogen receptors has been identified as a major prognostic and diagnostic biomarker of ER+ breast carcinoma and inhibition of ER is considered a gold standard in ER+ breast cancer treatment [8]. This evidence concerns the gene ESR1 and breast cancer.